Arvinas Inc (NAS:ARVN)
$ 33.9 -1.35 (-3.83%) Market Cap: 2.32 Bil Enterprise Value: 1.25 Bil PE Ratio: 0 PB Ratio: 3.80 GF Score: 66/100

Arvinas Inc at Citi BioPharma Conference Transcript

Sep 08, 2022 / 05:00PM GMT
Release Date Price: $48.42 (+6.75%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Great. So I'm Yigal Nochomovitz, I'm one of the biotech analysts here at Citi. It's my pleasure to have with me the senior management from Arvinas Therapeutics. Sean Cassidy, CFO, welcome.

Sean A. Cassidy
Arvinas, Inc. - CFO & Treasurer

Hello.

Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Nice to see you; and Ron Peck, Chief Medical Officer.

Ronald A. Peck
Arvinas, Inc. - Chief Medical Officer

Hello.

Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Nice to see both of you.

Questions & Answers

Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

So protein degradation is obviously a super inter platform. You're one of the pioneers. There are other companies in the space too. So maybe just to level set, give us a sense for what the mission is at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot